Publish time: 2024-01-03 00:00:00
11A-1120808
US provisional
Natural killer (NK) cells are promising for cancer immunotherapy owing to potent cytotoxicity, unique cancer recognition and safe allogeneic transfer. Lentiviral transduction is the mainstream method to genetically modify human NK cells, but the process is costly and low throughput. Plasmid DNA is a popular vector straightforward to construct and prepare; however, plasmid is highly toxic to NK cells. The Invention uses CRISPR genome editing to modify NK cells to alleviate plasmid toxicity. The CRISPR-edited NK cells tolerate plasmid toxicity and allow robust transgene expression from plasmid. The CRISPR-edited NK cell platform enables rapid customization and validation of chimeric antigen receptors (CAR) and pharmaceutically active biologics to enhance NK cell immunotherapy.
- Fast turnaround from CAR sequence to anti-cancer efficiency (3 vs. 15-20 days)
- High-throughput customization of CAR and any gene cargo
- Scalable to automated 96-well format
- Reduced cost without expensive virus production
- Compatible with BSL1
- Provide high-throughput customization and validation of CAR and pharmaceutically active gene cargos for NK cell immunotherapy
- Increase the production of NK cell therapeutics by transiently enhancing NK cell activation and rejuvenation
- Integrate with therapeutic antibody engineering to develop next generations of CAR against neoantigens
Steven Lin
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

A rapid and robust plasmid-based transgene expression and validation platform for human natural killer cells